[2 significant stages in the management of mucoviscidosis: the French experience with dornase alfa (Pulmozyme) and the impact in international registries].
F
F
Brémont
J
J
Navarro
D002170:Canada / Q000453:epidemiology; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000453:epidemiology; D003850:Deoxyribonuclease I / Q000009:adverse effects / Q000627:therapeutic use*; D005100:Expectorants / Q000009:adverse effects / Q000627:therapeutic use*; D005602:France / Q000453:epidemiology; D006801:Humans; D007558:Italy / Q000453:epidemiology; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012042:Registries / Q000706:statistics & numerical data; D014481:United States / Q000453:epidemiology
D005100:Expectorants; D011994:Recombinant Proteins; C085693:DNASE1 protein, human; D003850:Deoxyribonuclease I
Deux étapes significatives dans la prise en charge de la mucoviscidose: l'expérience française de la dornase alfa (Pulmozyme) et l'impact du registre international.